Jennifer A. Arzt

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial

Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig et al. · Journal of Clinical Oncology · 2018 · 313 citations · Full text

Medicine, Hematology, Pharmacology +16

Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study

Matthew S. Davids, Andrew W. Roberts, Vaishalee P. Kenkre et al. · Clinical Cancer Research · 2021 · 69 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors

Anthony W. Tolcher, Patricia LoRusso, Jennifer A. Arzt et al. · Cancer Chemotherapy and Pharmacology · 2015 · 66 citations

Medicine, Oncology, Pharmacokinetics +11

Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy

Shuo Ma, John F. Seymour, Danielle M. Brander et al. · Blood · 2021 · 40 citations · Full text

Pharmacy, Pharmacotherapy, Immunotherapy +10

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study

Anthony W. Tolcher, Patricia LoRusso, Jennifer A. Arzt et al. · Cancer Chemotherapy and Pharmacology · 2015 · 38 citations

Medicine, Pharmacokinetics, Pharmacology +10